This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Biotech Stock Roundup: MRNA's Vaccine Update, GILD's CAR T Therapy Label Expansion
by Ekta Bagri
Regulatory and pipeline updates from bigwigs like Moderna (MRNA) and Gilead (GILD) have been the biotech sector's few key highlights during the past week.
Xencor (XNCR) Inks Deal With J&J for B-Cell Malignancy Treatment
by Zacks Equity Research
Xencor (XNCR) partners will J&J (JNJ) to develop and commercialize bispecific antibody candidates against B-cell malignancy. Resultantly, the stock gains.
Bristol Myers Squibb (BMY) Stock Moves -0.97%: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed at $58.93 in the latest trading session, marking a -0.97% move from the prior day.
Gilead (GILD) Files sBLA to FDA for Yescarta Label Expansion
by Zacks Equity Research
Gilead's (GILD) wholly owned subsidiary, Kite, submits an sBLA to the FDA for Yescarta to treat relapsed/refractory large B-cell lymphoma in the second-line setting.
Merck (MRK) to Acquire Acceleron, Build Rare Disease Portfolio
by Zacks Equity Research
Merck (MRK) is set to acquire rare diseases-focused company Acceleron Pharma for $11.5 billion and gain access to its promising phase III candidate.
FDA Accepts Bristol Myers (BMY) sBLAs for Opdivo Combo for ESCC
by Zacks Equity Research
The FDA accepts Bristol Myers' (BMY) sBLAs for Opdivo-based combinations as a potential treatment for esophageal squamous cell carcinoma.
Merck (MRK) Keytruda Meets Hepatocellular Carcinoma Study Goal
by Zacks Equity Research
Merck's (MRK) Keytruda achieves both primary and secondary endpoints in a phase III study evaluating the drug in patients with advanced hepatocellular carcinoma.
Acceleron (XLRN) Stock Up on Takeover Rumors for $11 Billion
by Zacks Equity Research
Acceleron (XLRN) up on rumors of a potential acquisition by a pharma giant for $11 billion or $180 per share.
Bristol Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed at $59.84 in the latest trading session, marking a -0.65% move from the prior day.
Onconova (ONTX) KRAS Inhibitor Shows Activity in Lung Cancer
by Zacks Equity Research
Onconova (ONTX) is developing a combination of its rigosertib plus Bristol-Myers' Opdivo for treating cancer with solid tumors. Preliminary data from the phase I/II study demonstrates disease control potential.
Incyte (INCY) Jakafi Wins FDA Approval for Chronic GVHD
by Zacks Equity Research
Incyte's (INCY) going gets good with another FDA approval - Jakafi for the treatment of chronic GVHD. However, the stock witnesses a decline despite the recent approvals.
bluebird (BLUE) Submits BLA for Gene-Therapy to Treat Thalassemia
by Zacks Equity Research
bluebird (BLUE) files BLA with the FDA for its gene therapy, betibeglogene autotemcel (beti-cel), in patients with transfusion-dependent ¿¿-thalassemia.
Nektar (NKTR) Signs Deals With Pfizer, Merck KGaA for NKTR-255
by Zacks Equity Research
Nektar (NKTR) signs a collaboration deal with Pfizer and Merck KGaA to develop a combination of its NKTR-255 with the latter's Bavencio for treating urothelial carcinoma.
Biotech Stock Roundup: Regulatory Updates From BIIB, BMY, EXEL, Setback for VRCA
by Ekta Bagri
Regulatory and pipeline updates from pharma giants like Biogen (BIIB) and Bristol Myers (BMY) have been some of the key highlights in the biotech sector during the past week.
Bristol Myers (BMY) Opdivo-Relatlimab Combo Gets Priority Review
by Zacks Equity Research
Bristol Myers (BMY) application for fixed-dose combination of LAG-3-blocking antibody relatlimab and immuno- oncology Opdivo gets priority review in the United States.
Bristol Myers Squibb (BMY) Stock Moves -1.32%: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed at $60.50 in the latest trading session, marking a -1.32% move from the prior day.
Merck (MRK) Keytruda Gets CHMP Nod for Severe Breast Cancer
by Zacks Equity Research
The CHMP recommends an approval of Merck's (MRK) Keytruda combo for the treatment of patients with metastatic triple-negative breast cancer.
Exelixis (EXEL) Gets FDA Nod for Cabometyx for Thyroid Cancer
by Zacks Equity Research
Exelixis (EXEL) gets FDA approval for a label expansion of Cabometyx for the treatment of locally advanced or metastatic differentiated thyroid cancer.
Bristol Myers' (BMY) Opdivo Combo for Gastric Cancer Gets CHMP Nod
by Zacks Equity Research
Bristol Myers' (BMY) Opdivo, in combination with chemotherapy, gets positive CHMP recommendation by the EMA for treating adults with gastric cancer, among others.
Bristol Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Bristol Myers Squibb (BMY) closed at $61.23, marking a -1.24% move from the previous day.
Bristol Myers Squibb (BMY) Stock Moves -0.71%: What You Should Know
by Zacks Equity Research
In the latest trading session, Bristol Myers Squibb (BMY) closed at $63.13, marking a -0.71% move from the previous day.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Top Stock Reports for Abbott, Intel & QUALCOMM
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Abbott Laboratories (ABT), Intel Corporation (INTC), and QUALCOMM Incorporated (QCOM).
BOLT Enters Into a Collaboration Agreement With Bristol Myers
by Zacks Equity Research
BOLT collaborates with Bristol Myers to investigate its pipeline candidate BDC-1001 in combination with the latter???s Opdivo.
FDA Orders Warnings on Pfizer, Lilly, AbbVie JAK Drug Labels
by Kinjel Shah
The FDA requires a heart-risk warning on the label of JAK inhibitor medicines, Pfizer's (PFE) Xeljanz/Xeljanz XR, Lilly (LLY)/Incyte's (INCY) Olumiant, and AbbVie's (ABBV) Rinvoq.